Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

详细信息    查看全文

• 作者：Eva Rettinger¹ ; ^{eva.rettinger@kgu.de} ; Michael Merker¹ ; Emilia Salzmann-Manrique¹ ; Hermann Kreyenberg¹ ; Thomas Krenn² ; Matthias D&uuml ; rken³ ; Jö ; rg Faber⁴ ; Sabine Huenecke¹ ; Claudia Cappel¹ ; Melanie Bremm¹ ; Andre Willasch¹ ; Shahrzad Bakhtiar¹ ; Andrea Jarisch¹ ; Jan Soerensen¹ ; Thomas Klingebiel¹ ; Peter Bader¹
• 关键词：Allogeneic hematopoietic stem cell transplantation ; Chimerism ; Minimal residual disease ; Pre-emptive immunotherapy
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：23
• 期：1
• 页码：87-95
• 全文大小：960 K
• 卷排序：23

文摘

Retrospective study of pre-emptive immunotherapy in childhood acute lymphoblastic leukemia after transplantation Additional data for close monitoring of chimerism and minimal residual disease for detection of a high risk of relapse Stop of immunosuppression and unmanipulated donor lymphocyte infusion is safe, feasible, and effective Approach for preventing relapse in acute lymphoblastic leukemia patients at risk Close monitoring and immunotherapy result in similar outcome for patients with and without molecular relapse after transplantation